FOXO4-DRI is the most elegant idea in anti-aging research—a peptide that kills zombie cells while leaving healthy ones alone. One mouse study made it famous. Eight years later, no human has been dosed in a clinical trial.

FOXO4-DRI is probably the most intellectually elegant compound on this entire site. The mechanism is genuinely beautiful. Senescent cells are damaged cells that have stopped dividing but refuse to die. They survive because a protein called FOXO4 grabs onto p53—the tumor suppressor that triggers cell death—and holds it hostage. FOXO4-DRI is a decoy peptide that competes with FOXO4 for that grip on p53. When it wins, p53 is freed, and the senescent cell dies. In healthy cells, FOXO4 is not elevated, so the peptide has nothing to compete with. The selectivity is built into the biology.

The 2017 paper that introduced FOXO4-DRI was published in Cell—one of the three most prestigious journals in biology. Peter de Keizer's team at Erasmus University Medical Center tested it in both naturally aged mice and fast-aging progeroid mice. The peptide restored fur density, running wheel activity, and kidney function. The paper was rigorous. The results were striking. Longevity communities treated it as a breakthrough. Peptide vendors started selling it within months.

And then the field went quiet. No Phase I trial was filed. No human dosing study appeared. The original lab moved on to structural biology and mechanism work. De Keizer founded Cleara Biotech in 2018. The company raised $2.5 million in seed financing in 2022 and developed two optimized candidates—CL04177 and CL04183. As of early 2026, neither has entered clinical trials. The most celebrated senolytic peptide in the world has been stuck in preclinical for eight years.

This matters because FOXO4-DRI does not exist in a vacuum. Dasatinib plus quercetin—a drug-plus-supplement combination—has already been tested in human trials. It has confirmed that senolytics reduce senescent cell burden in living people. The comparison is uncomfortable but essential. This article gives the mechanism full credit and evaluates the mouse data on its merits. It also explains why the gap between preclinical fame and clinical reality is the central fact of this compound's story.

Quick Facts: FOXO4-DRI at a Glance

What Is FOXO4-DRI?

Pronunciation: FOX-oh-four-dee-are-eye

As you age, some of your cells enter a state called senescence. They stop dividing, but they do not die. Instead, they sit in your tissues, pumping out inflammatory signals—a cocktail of cytokines, chemokines, and proteases collectively called the senescence-associated secretory phenotype (SASP). These "zombie cells" accumulate over a lifetime. They are linked to chronic inflammation, tissue dysfunction, and many age-related diseases. Removing them—a strategy called senolysis—is one of the most studied approaches in modern aging research.

FOXO4-DRI is a synthetic peptide designed to selectively kill these senescent cells. The name tells you how it works: FOXO4 is the protein it targets, and DRI stands for D-retro-inverso, the chemical design strategy that makes the peptide resistant to enzymatic breakdown.

The D-retro-inverso design is clever molecular engineering. Normal peptides are built from L-amino acids—the natural form found in all living organisms. FOXO4-DRI uses D-amino acids—the mirror image—assembled in reverse order. The result is a molecule whose side chains project in the same 3D orientation as the original, preserving its ability to bind its targets, but whose backbone is unrecognizable to the proteases that would normally destroy it within minutes. It is like writing a message backward in mirror script—it looks almost identical from the front, but the paper shredder cannot read it.

At 46 amino acids and approximately 2.5 kDa, FOXO4-DRI is one of the larger research peptides in the longevity space. This size contributes to its high cost of production and its current price point in the gray market.

Origins and Discovery

The story of FOXO4-DRI begins with a question about why senescent cells survive. By the mid-2010s, the field of cellular senescence was well established. Researchers knew that senescent cells accumulated with age, that they secreted inflammatory factors, and that removing them could improve health in animal models. The first-generation senolytics—dasatinib plus quercetin, navitoclax—were already being tested. But these compounds worked by targeting survival pathways that are also active in some healthy cells, limiting their selectivity.

Peter de Keizer's insight was to ask a different question: what keeps senescent cells alive at the molecular level? His team identified the FOXO4-p53 interaction as a critical survival mechanism. In senescent cells, the transcription factor FOXO4 binds to the tumor suppressor p53 in the nucleus, preventing p53 from migrating to the mitochondria and triggering apoptosis. This interaction is specific to senescent cells—FOXO4 accumulates during senescence but is present at low levels in normal cells. The therapeutic window was built into the biology.

The team designed FOXO4-DRI as a competitive inhibitor—a decoy peptide that mimics the FOXO4 binding surface and competes for p53 binding. They used the D-retro-inverso strategy to make the peptide protease-resistant in vivo. The results, published in Cell in March 2017, showed that FOXO4-DRI selectively killed senescent cells in culture and, when injected into aged and progeroid mice, restored tissue homeostasis across multiple organs.

De Keizer founded Cleara Biotech in 2018 to commercialize the approach. The company raised $2.5 million in seed financing in September 2022 and developed two optimized clinical candidates—CL04177 and CL04183—designed for cancer and chronic disease applications. As of 2024, Cleara had advanced to Pre-IND/IMPD studies. But no IND application has been filed, and no clinical trial has been initiated.

Mechanism of Action

The FOXO4-p53 Survival Axis in Senescent Cells

When a cell enters senescence—whether from DNA damage, telomere shortening, oncogene activation, or other stress—it activates both survival and death programs simultaneously. The outcome depends on which program wins. In cells that become senescent rather than dying, FOXO4 plays a decisive role.

FOXO4 is a forkhead box transcription factor. In senescent cells, its expression increases significantly. Elevated FOXO4 translocates to the nucleus, where it binds directly to the transactivation domain (TAD) of the tumor suppressor p53—specifically the TAD2 region. This binding sequesters p53 in the nucleus, preventing it from translocating to the mitochondria where it would activate the intrinsic apoptotic pathway through BAX and caspase-3.

The result: the cell has enough p53 to maintain its growth arrest (it stays senescent) but not enough free p53 to trigger cell death (it survives). FOXO4 favors senescence over apoptosis. The senescent cell persists.

How FOXO4-DRI Breaks the Lock

FOXO4-DRI is a competitive inhibitor of this interaction. The peptide binds to the p53 TAD with high affinity, displacing endogenous FOXO4. Once freed from FOXO4, p53 exits the nucleus and translocates to the mitochondrial outer membrane. There, it triggers BAX oligomerization, cytochrome c release, and caspase-3 activation—the canonical intrinsic apoptosis pathway. The senescent cell dies.

A July 2025 study in Nature Communications provided the first NMR solution structures of the p53 TAD in complex with both FOXO4 and FOXO4-DRI, confirming this mechanism at atomic resolution. The study also revealed that p53 phosphorylation at Serine 15—which is elevated in senescent cells—enhances the affinity of both FOXO4 and FOXO4-DRI for p53. This phosphorylation-dependent binding provides an additional selectivity layer: senescent cells have higher p53-Ser15 phosphorylation, making them more sensitive to FOXO4-DRI.

The Selectivity Window

The selectivity of FOXO4-DRI is not a property of the peptide—it is a property of the target biology. In senescent cells, FOXO4 is highly expressed and p53-Ser15 is elevated, creating abundant substrate for competition. In non-senescent cells, FOXO4 is present at basal levels and p53 is in its normal regulatory state. FOXO4-DRI has nothing to compete with. The therapeutic window is defined by the disease state, not by the drug.

This is what makes FOXO4-DRI mechanistically distinct from first-generation senolytics like dasatinib and navitoclax, which target BCL-2 family survival proteins that are also active in some healthy cell types.

Key Research

The Landmark Cell Paper (2017)

Baar et al., Cell, March 2017 (PMID 28340339). Peter de Keizer's team at Erasmus University Medical Center. This is the foundational study and the reason FOXO4-DRI exists in the longevity conversation.

Models tested: Both naturally aged mice AND XpdTTD/TTD progeroid (fast-aging) mice—a significant strength, as many senolytic studies use only one model.

Key results in progeroid mice: - Running wheel activity significantly increased (untreated XpdTTD/TTD baseline: 1.37 ± 0.54 km/day; wild-type controls: 9.37 ± 1.1 km/day) - Fur density restored - Kidney function improved (measured via plasma urea and creatinine) - Senescent cell burden reduced in target tissues

Key results in naturally aged mice: - Fur density restored - Renal function improved - Fitness markers improved

Safety: Well tolerated. No adverse effects on liver or kidney function. No toxicity signals at therapeutic doses.

Protocol: Intraperitoneal injection, 5 mg/kg, three doses on alternating days.

Limitations: Single study. Single lab. No independent replication in a separate institution. Mouse-to-human translation of senolytic peptides is entirely uncharted.

The Leydig Cell Aging Study (2020)

PMID 32727601. Published in Aging. Tested FOXO4-DRI in naturally aged mice to address age-related testosterone decline. Found that FOXO4 maintains viability of senescent Leydig cells (testosterone-producing cells in the testes). FOXO4-DRI selectively induced p53 nuclear exclusion and apoptosis in senescent Leydig cells, improved the testicular microenvironment, and alleviated age-related testosterone secretion insufficiency. This extends the FOXO4-DRI mechanism to reproductive tissue aging.

The Structural Biology Breakthrough (2025)

De Keizer et al., Nature Communications, July 2025. First NMR solution structures of the p53 transactivation domain in complex with FOXO4 and FOXO4-DRI. Confirmed that FOXO4-DRI binds to the disordered p53 TAD2 region, forming a transiently folded alpha-helical complex. Demonstrated that p53 phosphorylation at Serine 15 enhances affinity for both FOXO4 and FOXO4-DRI—providing a structural explanation for the selectivity toward senescent cells where p53-Ser15 is elevated.

The Keloid Fibroblast Study (2025)

Published in Communications Biology, February 2025. Demonstrated that FOXO4-DRI induces apoptosis specifically in senescent keloid fibroblasts by promoting nuclear exclusion of p53 phosphorylated at Ser15. Extends the mechanism to pathological fibrosis—suggesting applications beyond aging.

The Endothelial Cell Senescence Study (2025)

Published in Frontiers in Bioengineering and Biotechnology, January 2025. Showed that FOXO4-DRI regulates endothelial cell senescence via the p53 signaling pathway. Extends the mechanism to vascular aging.

The FOXO4-p53 Mechanistic Review

PMID 28426964. Review establishing the theoretical framework for FOXO4 as a regulator of senescent cell survival via p53 sequestration. Foundational paper for understanding why FOXO4-DRI was designed.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

No human being has received FOXO4-DRI in a clinical trial. No Phase I safety study, no pharmacokinetic study, no dose-finding study, no efficacy study. The compound has been in the published literature since March 2017—nine years—and the human evidence column is empty.

This is not for lack of scientific interest. The 2017 Cell paper generated enormous attention. Peter de Keizer founded Cleara Biotech in 2018 to commercialize the approach. The company raised $2.5 million in seed financing in 2022 and developed two optimized candidates—CL04177 and CL04183—for cancer and chronic disease indications. As of 2024, Cleara had advanced to Pre-IND/IMPD studies, the earliest stage of regulatory engagement. No IND application has been filed with the FDA. No clinical trial is registered on ClinicalTrials.gov.

The closest thing to human data is the self-experimentation community. An estimated dozens to low hundreds of individuals have used gray-market FOXO4-DRI via subcutaneous injection at doses ranging from 1 mg to 25 mg. No systematic adverse event data has been collected. No biomarker data has been published. The community cannot measure senescent cell burden with validated assays, so efficacy assessment is impossible. These reports are anecdotal and uninterpretable.

Meanwhile, the comparator compound—dasatinib plus quercetin (D+Q)—has completed four human trials confirming that senolytics reduce senescent cell burden in living people (Hickson 2019, Justice 2019, STAMINA 2025). D+Q has human pharmacokinetic data, human safety data, and human efficacy data. FOXO4-DRI has none.

What would need to happen for human evidence to emerge: A Phase I first-in-human safety and pharmacokinetic study, likely in cancer patients (Cleara's stated focus) or in a population with measurable senescent cell burden. This requires an IND or IMPD filing, GMP-grade drug product manufacturing, and institutional review board approval. At typical biotech timelines—and Cleara's current funding level—first human dosing is plausibly 3–5 years away, assuming no further delays.

Safety, Risks, and Limitations

Reported Safety Profile

In the 2017 Baar et al. study, FOXO4-DRI was well tolerated in mice at the therapeutic dose (5 mg/kg IP, three doses on alternating days). No adverse effects on liver or kidney function were reported. No toxicity signals were observed.

This is the entirety of the published safety data.

The p53 Interference Question

FOXO4-DRI works by freeing p53 from FOXO4 sequestration in senescent cells. p53 is the most studied tumor suppressor in biology—it is mutated or dysfunctional in more than half of all human cancers. Any compound that modulates p53 activity raises legitimate questions about cancer risk. The selectivity argument—that FOXO4-DRI only affects p53 in cells where FOXO4 is elevated—is mechanistically sound but has not been tested over long time periods or repeated dosing cycles in any species.

The Accumulation Question

D-retro-inverso peptides are protease-resistant by design. This is a therapeutic advantage (longer half-life, sustained activity) but also a theoretical risk. If FOXO4-DRI is not efficiently cleared from tissues, repeated dosing could lead to accumulation at levels that exceed the therapeutic window. No pharmacokinetic study has been published for FOXO4-DRI in any species.

The Translation Gap

Mouse senolytic studies do not reliably predict human outcomes. Mice have different senescent cell distributions, different SASP profiles, different immune clearance mechanisms, and dramatically shorter lifespans. The progeroid mouse model (XpdTTD/TTD) used in the 2017 study is a model of accelerated aging caused by a DNA repair deficiency—it is not the same as natural human aging. Results in this model may overestimate the effect in naturally aged organisms.

What We Do Not Know

• Human pharmacokinetics (absorption, distribution, metabolism, elimination)
• Maximum tolerated dose in humans
• Off-target effects in human tissues with varying FOXO4 expression
• Immune response to repeated DRI peptide exposure
• Long-term cancer risk from chronic p53 modulation
• Interaction with any medication, supplement, or other peptide
• Whether subcutaneous injection (the community route) achieves systemic distribution comparable to intraperitoneal injection (the mouse route)

Legal and Regulatory Status

FOXO4-DRI is not approved by the FDA or any regulatory agency for any indication. It is not explicitly banned from compounding pharmacies (unlike epitalon, which was banned in September 2023). It is sold by gray-market peptide vendors as a "research chemical—not for human consumption."

No IND (Investigational New Drug) application has been filed with the FDA. Cleara Biotech is in the Pre-IND/IMPD stage as of 2024, which is the earliest phase of regulatory engagement—before formal clinical trial authorization.

FOXO4-DRI is not listed on the WADA 2025–2026 Prohibited List.

The cost of FOXO4-DRI ($200–$1,000+ per vial from gray-market sources) is significantly higher than most peptides, reflecting the complexity of synthesizing a 46-amino-acid D-retro-inverso peptide. This cost barrier naturally limits community adoption.

Research Protocols and Formulation Considerations

Published research protocol (Baar et al., 2017): - Route: Intraperitoneal injection - Dose: 5 mg/kg - Schedule: Three injections on alternating days - Vehicle: Standard saline - Storage: Research-grade peptide, temperature not specified in publication (standard peptide storage: 2–8°C / 35–46°F for reconstituted solutions, −20°C / −4°F for lyophilized powder)

Allometric dose translation: The mouse IP dose of 5 mg/kg translates to approximately 0.4 mg/kg in humans by body surface area conversion—roughly 25 mg for a 60 kg adult or 30 mg for a 75 kg adult. This translation assumes equivalent bioavailability across routes, which is not established. IP injection in mice delivers directly to the peritoneal cavity with rapid absorption; subcutaneous injection in humans may have different pharmacokinetics.

No human formulation, route optimization, or dose-finding study has been published.

Dosing in Published Research

Published research doses: - Mouse IP: 5 mg/kg, three doses on alternating days (Baar 2017) - No other dosing regimen has been published in any species

There is no established human dose for FOXO4-DRI. The allometric mouse-to-human translation (~0.4 mg/kg) is a mathematical conversion, not a validated therapeutic dose.

Detailed Research Dosing Data (from published studies)

Study Model Route Dose Schedule Duration Baar et al., Cell (2017) Aged and XpdTTD/TTD mice Intravenous (IV) infusion Not publicly specified in simple units; described as concentration in infusion 3 times per week (inferred) 3 weeks That’s the entire published human dosing dataset for FOXO4-DRI: zero entries. The 2017 mouse study did not publish the exact dose in terms that easily translate to human equivalents (mg/kg body weight, mg/m² surface area, or molar dose). The actual concentration in the infusion and the total volume administered per treatment are stated in the paper, but the numeric values require careful reading of the supplementary methods.

Dosing in Self-Experimentation Communities

Community use of FOXO4-DRI is limited compared to other longevity peptides, primarily due to cost. The available community reports suggest:

• Typical dose range: 1–25 mg subcutaneous injection
• Typical protocol: Daily or every-other-day injections for 1–3 weeks
• Higher-end protocols: Some self-experimenters use the allometric translation of ~25 mg per dose, three doses on alternating days, mirroring the mouse protocol
• Lower-end protocols: Some report titrating from 250–500 mcg daily, escalating over weeks

Critical context: No dose-response relationship has been established for FOXO4-DRI at any dose in any species via subcutaneous injection. The community is not titrating toward an optimum—it is guessing in the dark. The wide range of reported doses (1 mg to 25 mg) reflects the absence of pharmacological guidance, not individual variation around a known target.

Community adverse event reporting is anecdotal and unsystematic. No formal adverse events have been documented. The small user base (estimated dozens to low hundreds) means that rare adverse events would be statistically invisible even if they occurred.

Combination Stacks

Research into FOXO4-DRI combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining FOXO4-DRI with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

The Dasatinib + Quercetin Comparison

This section exists because no honest assessment of FOXO4-DRI can ignore the elephant in the room. Dasatinib plus quercetin (D+Q) is the most clinically validated senolytic combination in the world, and it has already achieved what FOXO4-DRI has not: proof that senolytics work in living humans.

• First-in-humans senolytic trial (2019): Open-label pilot in patients with diabetic kidney disease. Three days of oral dasatinib (100 mg) plus quercetin (1,000 mg). Confirmed that senolytics significantly decrease senescent cell burden in living humans. Published in EBioMedicine.

• Idiopathic Pulmonary Fibrosis trial: 14 patients with stable IPF. Intermittent D+Q over three weeks. Well tolerated. Improved physical function in a fatal senescence-associated disease.

• STAMINA study (2025): 12-week pilot in 12 older adults (age 65+) with slow gait and mild cognitive impairment. Intermittent D+Q. Feasible, safe, and showed hints of functional benefit. Published in eBioMedicine.

This comparison is not a criticism of FOXO4-DRI's science. The mechanism is arguably more elegant than D+Q's, and the selectivity story is more compelling. But elegance does not equal evidence, and the human data gap is not a minor detail—it is the defining characteristic of this compound's current profile.

Peptidings includes this comparison because our readers deserve to know that a cheaper, better-studied senolytic combination exists while they consider paying a premium for an untested one.

Frequently Asked Questions

Summary of Key Findings

FOXO4-DRI is the compound that makes you love the science and grieve the timeline. The mechanism is the most elegant senolytic design in the literature—a peptide that exploits a survival interaction unique to senescent cells, confirmed at atomic resolution by NMR in 2025. The mouse data is real and striking. And none of it has been tested in a single human being.

The mechanism is confirmed and increasingly well understood. The FOXO4-p53 survival axis in senescent cells is established. FOXO4-DRI competitively displaces FOXO4, frees p53, and triggers apoptosis selectively in senescent cells. The 2025 Nature Communications paper confirmed this at the structural level—the first NMR structures of the actual molecular interaction. The selectivity story is mechanistically sound: it depends on FOXO4 elevation in senescent cells and p53-Ser15 phosphorylation, both of which are senescence-specific. This is not hand-waving. This is characterized.

The 2017 mouse study is strong but unreplicated. The Baar et al. Cell paper tested FOXO4-DRI in both naturally aged and progeroid mice—a significant strength. It measured functional endpoints (fitness, fur, kidney function), not just biomarkers. The results were striking. But this study has not been independently replicated by a separate institution. The mechanism has been confirmed in new cell types (Leydig cells, keloid fibroblasts, endothelial cells), but the whole-animal aging reversal experiment remains a single-lab result.

Eight years of preclinical stasis is the defining fact. FOXO4-DRI was published in Cell in March 2017. As of March 2026, no Phase I trial has been initiated. No IND has been filed. Cleara Biotech raised $2.5 million in 2022—a modest seed round—and has developed optimized candidates but has not entered clinical development. The reasons are mundane: insufficient funding, the long timelines of drug development, and a pivot from aging to cancer indications. But the result is the same: the most celebrated senolytic peptide in the world has been preclinical for nine years.

The D+Q comparison is devastating. Dasatinib plus quercetin has been tested in multiple human trials. The first-in-humans senolytic trial (2019) confirmed that D+Q reduces senescent cell burden in living people. The STAMINA study (2025) showed safety and feasibility in older adults with cognitive impairment. D+Q costs approximately $10 per treatment course. FOXO4-DRI costs $200–$1,000+. FOXO4-DRI may have a more selective mechanism. But unproven selectivity is not a substitute for proven efficacy, and the human evidence gap is not a matter of nuance—it is a chasm.

Community use is limited and uninterpretable. The high cost of FOXO4-DRI limits adoption to dozens or low hundreds of self-experimenters—far fewer than BPC-157, epitalon, or other popular peptides. Reported doses range from 1 mg to 25 mg—a 25-fold spread. No reliable method exists for self-experimenters to assess whether the compound is working. The community cannot generate meaningful safety or efficacy signal at this scale.

The p53 modulation question is open. FOXO4-DRI works by freeing p53, which should be tumor-suppressive. But chronic modulation of the most important tumor suppressor in human biology is not a casual matter. No long-term safety data exists in any species. The cancer risk question has not been studied.

Verdict Recapitulation

FOXO4-DRI earns Tier 4 because no human clinical trial data exists. One mouse study and expanding in vitro work constitute the entirety of the evidence base. The tier reflects the current state of human evidence, not the quality of the preclinical science.

The compound earns "Eyes Open" rather than "Thin Ice" because the underlying science is genuinely strong. The 2017 Cell paper was rigorous. The mechanism is confirmed at atomic resolution. The selectivity story is mechanistically compelling. And the expanding body of 2025 publications shows that the science is progressing, even if clinical translation is not.

But "Eyes Open" also means this: you should know exactly what you are buying. FOXO4-DRI is the most celebrated preclinical compound in the senolytic space, and it has been preclinical for nine years. A cheaper, better-studied senolytic combination (D+Q) has already been tested in humans. The mechanism is beautiful. The mouse data is strong. The human evidence is zero. If you are considering FOXO4-DRI, your eyes should be wide open—not because the science is bad, but because the distance between elegant preclinical science and proven human therapy is measured in clinical trials that have not happened.

For readers deciding between FOXO4-DRI and other senolytics: read the D+Q comparison in Section 10. Understand the cost difference. Understand the evidence difference. Then decide what you are willing to pay—in money and in uncertainty—for a more selective mechanism that has not been tested in your species.

For readers considering FOXO4-DRI, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source FOXO4-DRI

Further Reading and Resources

If you want to go deeper on FOXO4-DRI, the evidence landscape for longevity & anti-aging peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Longevity & Anti-Aging Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: FOXO4-DRI — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Baar et al., "Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging." Cell, 2017 PubMed
2. De Keizer et al., "The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI." Nature Communications, July 2025
3. FOXO4-DRI Leydig cell aging study, "FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice." Aging, 2020 PubMed
4. Keloid fibroblast study, "FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation." Communications Biology, February 2025
5. Endothelial cell senescence study, "FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway." Frontiers in Bioengineering and Biotechnology, January 2025
6. Baar et al., "Regulation of cellular senescence via the FOXO4-p53 axis." EMBO Reports, 2017 PubMed
7. Justice et al., "Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study." EBioMedicine, 2019
8. Hickson et al., "Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease." EBioMedicine, 2019
9. STAMINA study, "Senolytics To Alleviate Mobility Issues and Neurological Impairments in Ageing." eBioMedicine, 2025
10. Cleara Biotech seed financing announcement, BusinessWire, September 2022
11. Baker et al., "Naturally occurring p16Ink4a-positive cells shorten healthy lifespan." Nature, 2016. —Foundational senescent cell clearance study demonstrating that removing senescent cells extends healthspan in mice PubMed
12. Zhu et al., "The Achilles' heel of senescent cells: from transcriptome to senolytic drugs." Aging Cell, 2015. —Discovery of dasatinib + quercetin as senolytic combination PubMed
13. —FOXO4-DRI related research (requires direct verification) PubMed
14. Fight Aging!, "Cleara Biotech Launches to Develop Senolytic Therapies Based on FOXO4-DRI." July 2018
15. Fight Aging!, "How to Plan and Carry Out a Simple Self-Experiment, a Single Person Trial of Senolytic Peptide FOXO4-DRI." March 2018

---